Trending NewsTrending NewsNASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis $42.69 -0.55 (-1.27%) Closing price 04:00 PM EasternExtended Trading$43.03 +0.34 (+0.80%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ionis Pharmaceuticals Stock (NASDAQ:IONS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ionis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$42.09▼$43.7250-Day Range$35.24▼$43.7852-Week Range$23.95▼$50.43Volume1.86 million shsAverage Volume2.17 million shsMarket Capitalization$6.80 billionP/E RatioN/ADividend YieldN/APrice Target$60.85Consensus RatingModerate Buy Company Overview Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California. Read More Ionis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreIONS MarketRank™: Ionis Pharmaceuticals scored higher than 93% of companies evaluated by MarketBeat, and ranked 87th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.50) to ($2.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -23.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -23.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 10.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ionis Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.45% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently decreased by 10.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-3.58 Percentage of Shares Shorted7.45% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently decreased by 10.16%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.92 News SentimentIonis Pharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Ionis Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 9 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,644,606.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Stock News HeadlinesC Frank Bennett Sells 10,000 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) StockAugust 21 at 8:00 AM | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Sells $209,650.00 in StockAugust 9, 2025 | insidertrades.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 22 at 2:00 AM | Timothy Sykes (Ad)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Richard S. Geary Sells 10,000 SharesAugust 7, 2025 | insidertrades.comEugene Schneider Sells 9,549 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockAugust 6, 2025 | insidertrades.comIonis Pharmaceuticals price target raised to $69 from $65 at Citi5 hours ago | msn.comIonis Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright5 hours ago | msn.comIonis Pharmaceuticals price target raised to $58 from $57 at BarclaysAugust 22 at 9:45 AM | msn.comSee More Headlines IONS Stock Analysis - Frequently Asked Questions How have IONS shares performed this year? Ionis Pharmaceuticals' stock was trading at $34.96 on January 1st, 2025. Since then, IONS shares have increased by 22.1% and is now trading at $42.69. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings data on Wednesday, July, 30th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.19 by $0.51. The company's revenue for the quarter was up 100.9% on a year-over-year basis. Read the conference call transcript. Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' top institutional shareholders include Adage Capital Partners GP L.L.C. (2.38%), Tweedy Browne Co LLC (1.82%), Geode Capital Management LLC (1.81%) and Groupama Asset Managment (0.73%). Insiders that own company stock include Brett P Monia, Elizabeth L Hougen, C Frank Bennett, Richard S Geary, B Lynne Parshall, Brian Birchler, Patrick R O'neil, Eugene Schneider, Michael R Hayden, Eric Swayze, Onaiza Cadoret-Manier, Joseph Baroldi, Joseph Klein III and Allene M Diaz. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings7/30/2025Today8/22/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees1,069Year FoundedN/APrice Target and Rating Average Price Target for Ionis Pharmaceuticals$60.85 High Price Target$82.00 Low Price Target$39.00 Potential Upside/Downside+42.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$453.90 million Net Margins-28.25% Pretax Margin-29.04% Return on Equity-45.29% Return on Assets-8.99% Debt Debt-to-Equity Ratio0.99 Current Ratio2.87 Quick Ratio2.86 Sales & Book Value Annual Sales$705 million Price / Sales9.65 Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book10.78Miscellaneous Outstanding Shares159,390,000Free Float155,247,000Market Cap$6.80 billion OptionableOptionable Beta0.25 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:IONS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.